[10-11]ABIN-1在细胞程序性坏死（Necroptosis）中的作用和调控机制研究以及基于Necroptosis的肿瘤治疗策略的探索

报告题目：ABIN-1在细胞程序性坏死（Necroptosis）中的作用和调控机制研究以及基于Necroptosis的肿瘤治疗策略的探索

报 告 人：苏振毅（东南大学医学院 讲师）
报告时间：2017年10月11日（星期三）下午1:00
报告地点：独墅湖校区二期云轩楼2301室

报告摘要：
ABIN-1 (A20 binding and inhibitor of NF-κB 1) is known to be a negative regulator of inflammation and apoptosis. However, we reveal that ABIN-1 is not restricted to regulate apoptosis, but also involved in regulation of necroptosis. In addition, ABIN-1 deficiency may transform the cell death patterns of certain classic pro-apoptotic drugs. This talk will discuss the molecular mechanism that ABIN-1 regulates necroptosis and the physiological function. Necroptosis-based cancer therapy is a novel strategy for cancer treatment emerging in recent years. Necroptosis can execute a tumor cell in caspases-deficient or -compromised condition, thus necroptosis-based cancer therapy may provide a new way for solving the chemotherapeutic drugs resistance problem. This talk will discuss the directions and concerns this new strategy.

报告人简介：
苏振毅，2012年博士毕业于北京师范大学生命科学学院，现在东南大学医学院工作，主要从事肿瘤免疫、肿瘤分子治疗、细胞死亡等方面的研究。2014.7-2016.1期间，在美国哈佛医学院开展细胞程序性坏死(Necroptosis)的调控研究。主持国家自然基金面上项目、青年基金等多个项目，在Nature Cell Biology, Cell Death and Differentiation, Cell Death & Disease, The Journal of Immunology, EBioMedicine等杂志发表论文10余篇。